glaxosmithkline biologicals sa

What glaxosmithkline biologicals sa does

GlaxoSmithKline Biologicals SA is the Belgian operating entity of GSK plc focused on vaccine discovery, development, and manufacturing, headquartered in Rixensart with production facilities in Wavre, Rixensart, and Gembloux. The entity operates the largest vaccine production site in the world (Wavre) and is part of the world's largest industrial vaccine network, with 13 production sites across four continents producing 863+ million doses annually from approximately 30 different vaccines. Its portfolio includes 20+ commercial vaccines covering infants, adolescents, and adults, including notable products such as Rotarix (rotavirus), Cervarix (HPV), Synflorix (pneumococcal), shingles vaccine, and the world's first approved RSV vaccine. The company is investing €1.3 billion in R&D in Belgium in 2025 alone, with an additional 20 vaccines in development.

The business model centers on B2B/B2G sales of vaccines to national governments, healthcare providers, and supranational organizations such as WHO and Gavi, with six out of ten doses destined for large-scale vaccination campaigns in developing countries. Vaccines are exported to 160+ countries at a rate of 1 million doses daily from the Gembloux logistics center. Underlying technology platforms include advanced lyophilization (freeze-drying) with eco-friendly cooling systems, automated infrared visual inspection for quality control, autonomous mobile robots for warehouse operations, and variable temperature storage infrastructure. The entity employs approximately 8,500-9,000 people in Belgium, making GSK the largest pharmaceutical employer in the country, with 1,800+ scientists dedicated to vaccine development within a broader 12,000+ global vaccines workforce.

The entity operates as part of GSK plc, a publicly traded company on the London Stock Exchange under ticker GSK. Strategic positioning emphasizes Belgium as the 'Silicon Valley of Vaccines' with end-to-end capabilities from R&D through global export, supported by co-development partnerships with Belgian academic institutions including the University of Antwerp's Vaccinopolis research center. Recent capital investments totaling over €300 million (€250M lyophilization center, €50M warehouse) signal continued prioritization of Belgian operations within GSK's global vaccine strategy.

Name

glaxosmithkline biologicals sa

Legal name

GlaxoSmithKline Biologicals SA

Website

https://gsk.be

Company type

Public

Founded year

1945

Operating status

Operating

Short description

GlaxoSmithKline Biologicals SA is the Belgian vaccine operating entity of GSK plc, operating the world's largest vaccine production network with 8,500 employees across three Belgian sites. It manufactures and exports 20+ vaccines to 160+ countries, serving governments, healthcare providers, and supranational organizations.

Ownership category

akta.pro rank

Product category

Vaccines and Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Human vaccines
• Biopharmaceutical manufacturing
• Vaccine development
• Respiratory disease treatments
• Infectious disease prevention

Headquarters

HQ city

Rixensart

HQ country

Belgium

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Supply Chain, Operations

Revenue model

1. Vaccines: GSK manufactures and commercializes a portfolio of more than 20 vaccines for infants, adolescents, and adults, with 20 more vaccines in development. Revenue generated through direct sales to governments, healthcare providers, and supranational organizations like WHO and Gavi.
2. Pharmaceutical Medicines: GSK discovers, develops, and delivers medicines targeting respiratory diseases, immunology and inflammation, oncology, HIV, and infectious diseases.
3. Vaccine Development Partnerships: Collaboration with academic institutions, contractors, and authorities for vaccine research, development, and production.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

GlaxoSmithKline Biologicals SA discovers, develops, and manufactures a portfolio of more than 20 vaccines and related biopharmaceuticals for infants, adolescents, and adults, with another 20 vaccines in development. From its Belgian sites at Wavre, Rixensart, and Gembloux, the company produces respiratory syncytial virus (RSV), shingles, rotavirus, HPV, pneumococcal, measles, and varicella vaccines, exporting them to over 160 countries worldwide.

Product overview

GSK (GlaxoSmithKline Biologicals SA) is a focused biopharma company that discovers, develops, and delivers medicines and vaccines. In Belgium, GSK operates the world's largest industrial vaccine network across three main sites in Wavre, Rixensart, and Gembloux. The company offers a portfolio of over 20 approved vaccines including Rotarix (rotavirus), Cervarix (HPV), Synflorix (pneumococcal), and the groundbreaking RSV vaccine (first in the world), with 20 additional vaccines in development. GSK's product portfolio spans vaccines for respiratory diseases, infectious diseases, HPV, and various other conditions, exported to over 160 countries globally.

Differentiator

Problem solved

Functional benefit

Brands

• GSK Vaccines: Vaccines division of GSK operating from Belgian sites
• GSKPro
• Global Vaccines Commercial (GVC)

Products and services

• RSV Vaccine (Respiratory Syncytial Virus Vaccine)
• Shingles (Zona) Vaccine
• Rotarix
• Cervarix
• Synflorix
• Measles Vaccine
• Varicella Vaccine
• Vaccines Portfolio (20+ commercial vaccines, 20 in development)

Quantifiable outcome

• World's first approved RSV vaccine, now authorized in over 60 countries
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core.

• Yusen LogisticscoreChannel Partner/ Reseller/ Distributor · 24 June 2024Yusen Logistics Benelux operates the new 40,000 m² pharmaceutical warehouse at Gembloux, the largest biopharma logistics center in Wallonia. The partnership includes an on-site packaging solutions center ensuring product integrity during transport through passive packaging solutions adapted to all transport modes. Yusen provides freight forwarding, warehouse management, distribution, and end-to-end supply chain management services.
• MG Real EstatecoreImplementation/ SI/ Consulting Partner · 24 June 2024MG Real Estate developed the 40,000 m² pharmaceutical warehouse at Gembloux, the largest biopharma logistics center in Wallonia. As a European property developer, MG Real Estate transformed industrial brownfield sites into modern logistics facilities meeting BREEAM 'excellent' sustainability standards.
• Belgian GovernmentcoreStrategic or Co-development Partner · 30 August 2023Belgian Prime Minister Alexander De Croo, Vice-Premier ministre Pierre-Yves Dermagne, and Vice-President of Wallonia Willy Borsus attended the inauguration of the new lyophilization center, demonstrating government support for GSK's pharmaceutical manufacturing investments.
• Vaccinopolis / University of AntwerpcoreStrategic or Co-development PartnerVaccinopolis research center in Belgium conducted 15 clinical studies on the RSV vaccine, involving approximately 3,000 volunteers. University of Antwerp researchers contributed to mapping the specific immune response induced by the vaccine and documenting its epidemiology in Belgium and Europe.
• Belgian Academic InstitutionscoreStrategic or Co-development PartnerBelgian universities and research centers collaborate with GSK on vaccine research and development, contributing to clinical studies and immunological research for various vaccine candidates.
• Belgian Health AuthoritiescoreStrategic or Co-development PartnerBelgian regulatory authorities collaborate with GSK from the early stages of research and development, facilitating the approval and rollout of innovative vaccines.

Scale indicators16 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Sanofi Pasteur: Sanofi Pasteur is the vaccines division of Sanofi and one of the largest global vaccine manufacturers, producing a broad pediatric and adult vaccine portfolio (including RSV and influenza). It is GSK Biologicals' most direct global competitor across nearly every major vaccine category.
• Pfizer: Pfizer is a major global vaccine manufacturer with a deep portfolio spanning pneumococcal, RSV (Abrysvo), COVID-19, and other indications. Pfizer competes directly with GSK in adult and pediatric vaccines and is a leading counterpart in supranational procurement.
• Merck & Co. (MSD): MSD manufactures vaccines across multiple categories including HPV (Gardasil), pediatric combinations, and pneumococcal disease. It is a top-tier direct competitor to GSK in both routine immunization and adult vaccine markets globally.

Emerging players

• Moderna: Moderna is an mRNA-based vaccine developer with approved COVID-19 and RSV vaccines and a pipeline across influenza and other indications. It represents a platform-based competitive threat to GSK's traditional vaccine technologies, particularly in respiratory indications.
• BioNTech: BioNTech is an mRNA vaccine company co-developing COVID-19 and other vaccines with Pfizer, with active programs in influenza, RSV, and oncology. It is a platform-level emerging competitor whose technologies could disrupt GSK's traditional vaccine franchises.
• Bavarian Nordic: Bavarian Nordic is a Danish vaccine company with approved vaccines in smallpox/monkeypox, RSV, and other infectious diseases. It is an emerging direct competitor particularly in the adult RSV vaccine market where GSK holds first-mover advantage.
• Novavax: Novavax is a recombinant protein nanoparticle vaccine developer with an approved COVID-19 vaccine and pipeline in influenza and other indications. Its protein-subunit platform overlaps with portions of GSK's technology base, making it a comparable emerging competitor.

Broad incumbents

• Johnson & Johnson (Janssen): Janssen Vaccines, part of J&J, develops and commercializes vaccines including Ebola and respiratory programs. As a diversified pharma incumbent with a vaccine franchise, it competes with GSK in select indications while operating across a much broader portfolio.

Regional players

• Sinovac Biotech: Sinovac is a China-based vaccine manufacturer with products in hepatitis, influenza, COVID-19, and pediatric vaccines. It is a major regional supplier to Asian and developing-country markets where GSK also sells through supranational channels, making it a comparable in low/middle-income geographies.
• Bharat Biotech: Bharat Biotech is an India-based vaccine manufacturer with a broad pediatric and adult portfolio including rotavirus, polio, and COVID-19 vaccines. It is a major supplier to Gavi and developing-country markets that overlap with GSK's supranational organization distribution channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about glaxosmithkline biologicals sa